Company intelligence / Profile preview
89bio
San Francisco, California, United States89bio.com ↗
- Ownership
- Public · ETNB
- Employees
- ~85
- Development stage
- Phase 3
01
Overview
The company is currently conducting Phase 3 trials for its lead candidate pegozafermin for MASH with advanced fibrosis (including patients with compensated cirrhosis) and SHTG. They have completed enrollment in their Phase 3 ENTRUST trial in SHTG as of February 2025[6].
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic Disorders
- Modalities
- FGF21 analog (glycoPEGylated FGF21)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on 89bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89bio.